Kornimate/medical-research-clean huggingface dataset:
the effect of conscious awareness development psychoeducation program prepared for caregivers

Conditions: Mental Health Issue

Summary: this study aimed to increase the conscious awareness of caregivers and reduce work stress and compassion fatigue.

this study was planned in an experimental design with pre-test post-test follow-up measurements, experimental and control groups. the universe of the study consisted of care personnel working in institutions affiliated to the provincial directorate of family, labor and social services located in a city center in the east of turkey. the sample calculation was made using the g-power program (experiment 14, control 14). since there may be omissions, the experimental group was determined as 20 participants and the control group as 20 participants. in this study, a nine-session training program will be applied to the experimental group. no application will be made to the control group. the conscious awareness development psychoeducation program will be applied once a week and for 90 minutes. each session will be conducted in line with certain objectives. the sessions will be conducted by the investigator. ethics committee approval was obtained before starting the study. institutional permissions and written informed consent will be obtained for the participants. informed consent will include information about the research and information that will ensure confidentiality.

Eligibility criteria:
inclusion criteria: * being over 18 years of age, * being actively working as a care worker in relevant institutions. exclusion criteria: * having received similar training before * having been diagnosed with a mental illness * wanting to leave the study at any stage. * not having attended more than two sessions.

Keywords: mindfulness, work stress compassion fatigue psychoeducation
physical training on patients with breast cancer

Conditions: Breast Cancer Female

Summary: the treatment of breast cancer at any given time can be through surgery, as well as adjuvant treatments (radiotherapy, chemotherapy and hormone therapy) alone or together. and with this the patient tends to lose weight, he becomes depressed, resulting in an increasingly debilitating picture. therefore, the present study aims to investigate the relationship between physical exercise and its effects on quality of life in patients with breast cancer, those who underwent surgery for at least 6 months, patients who are still with the tumor using the adjuvant treatments submitted to physical exercises and not submitted. the sample will consist of 25 to 50 female patients aged 18 to 75 years. patients will be submitted to the initial quality of life evaluation (sf - 36 reduced version, anxiety and depression (had scale), fatigue (piper fatigue scale), pain (brief inventory of pain), body composition (bioimpedance byodinamics 450 ) and oxidative stress markers (oxidized and reduced glutathione, tbars / mda, myeloperoxidase and creatinine), inflammatory markers (il1, il6, il8, il10, mcp-1 and tnf-α), hormones estrogen, progesterone), blood test (complete blood count) 24 hour food recall (24hs food recall), and perform the maximum repetition test to find the initial workload that will be adjusted every 4 weeks with the evaluation of the load and completing the 12 weeks of training will be reevaluated following the initial evaluation. the data collected will be treated statistically with an α=5% using the software stata 12.0.

the patients will be allocated into two groups: exercise group (intervention) and conventional treatment group (active comparison). intervention: the combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of flexibility training (unsupervised). as stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.

Eligibility criteria:
inclusion criteria: * breast cancer patients; * sedentary; * currently at treatment and clinical follow-up. exclusion criteria: * musculoskeletal injuries or disorders; * mental illnesses; * enrolled in other exercise program.
dual thrombolytic therapy with mutant pro-urokinase and low dose alteplase for ischemic stroke

Conditions: Ischemic Stroke

Summary: randomized controlled phase ii trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (iv) bolus of alteplase followed by iv infusion of mutant pro-urokinase against usual treatment with iv alteplase in patients presenting with ischemic stroke.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of ischemic stroke; * a score of at least 1 on the nih stroke scale; * ct ruling out intracranial hemorrhage; * treatment possible within 4.5 hours from symptom onset or last seen well; * meet the criteria for standard treatment for iv alteplase according to national guidelines27; * age of 18 years or older; * written informed consent (deferred). exclusion criteria: * candidate for endovascular thrombectomy (i.e., a proximal intracranial large artery occlusion on cta); * contra-indication for treatment with iv alteplase according to national guidelines27: * arterial blood pressure exceeding 185/110 mmhg and not responding to treatment * blood glucose less than 2.7 or over 22.2 mmol/l * cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging * head trauma in the previous 4 weeks * major surgery or serious trauma in the previous 2 weeks * gastrointestinal or urinary tract hemorrhage in the previous 2 weeks * previous intracerebral hemorrhage * use of anticoagulant with inr exceeding 1.7 or aptt exceeding 50 seconds * known thrombocyte count less than 90 x 109 /l * treatment with direct thrombin or factor x inhibitors, unless specific antidotum has been given, i.e. idarucizumab in case of dabigatran use. * pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mrs \> 2; * known pregnancy or if pregnancy cannot be excluded, i.e. did not have intercourse for \> 6 months and no clinical signs of pregnancy, adequate use of any contraceptive method (e.g. intrauterine devices) or sterilization of the subject herself. * contra-indication for an mri scan, i.e.: * an mri incompatible pacemaker, icd, pacing wires and loop records * metallic foreign bodies (e.g. intra-ocular) * prosthetic heart valves * blood vessel clips, coils or stents * an implanted electronic and/or magnetic implant or pump (e.g. neurostimulator) * cochlear implants * mechanical implants (implanted less than 6 weeks ago) * a copper intrauterine device * current participation in any medical or surgical therapeutic trial other than dumas.

Keywords: randomized controlled trial thrombolytic treatment intracranial hemorrhage mutant pro-urokinase ischemic stroke
phase iia randomized placebo controlled trial: mesenchymal stem cells as a disease-modifying therapy for idiopathic parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (msc) infusions to slow the progression of parkinson's disease (pd).

single site phase iia study of allogeneic msc in a double blind randomized control trial as disease modifying therapy for pd. the design includes three treatment arms with 45 patients.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease by the uk brain bank criteria including the presence of 2 cardinal signs of pd plus bradykinesia. * mild microsomia to anosmia. * a modified hoehn and yahr stage of 3 or less. * date of diagnosis of pd between 3 to 10 years * robust response to dopaminergic therapy. exclusion criteria: * atypical, vascular, or drug-induced parkinsonism. * an atypical dat scan or mri supporting an alternative explanation for pd symptoms. * patient not on levodopa containing medications. * clinical features of psychosis or refractory hallucinations. * a montreal cognitive assessment (moca) score of less than 25. * uncontrolled seizure disorder. * abnormal kidney and liver function. * presence of clinically refractory orthostatic hypotension at the screening or baseline visit. * body mass index of greater than or equal to 35. * cardiac disease: history of congestive heart failure, clinically significant bradycardia, presence of 2nd, or 3rd-degree atrioventricular block. * pulmonary disease: copd with oxygen-requirement at rest or with ambulation; or moderate to severe asthma. * active malignancy or diagnosis of malignancy within 5 years prior to the start of screening * any current suicidal ideation or behaviors. * any diagnosis of autoimmune disease or immunocompromised state * history of medium or large size vessel cerebrovascular accidents. * history of traumatic brain injury with loss of consciousness and residual neurologic symptoms. * major surgery within the previous 3 months or planned in the ensuing 6 months. * history of use of an investigational drug within 90 days prior to the screening visit. * history of brain surgery for pd. * substance abuse disorder. * active anticoagulation treatment and/or abnormal inr.

Keywords: stem cells mesenchymal stem cells inflammatory markers
homologous prp vs placebo in knee osteoarthritis in over 65 years old patients

Conditions: Knee Osteoarthritis

Summary: the aim of the study is to compare the 6 months clinical outcome of the treatment with a single injection of homologous prp versus single injection of placebo (saline solution) in the infiltrative treatment of knee osteoarthritis in over 65 years old patients. the evaluation will be performed through clinical, subjective and objective assessments.

204 patients affected by knee osteoarthritis will be included in a double-blinded rct with possibility ,after 6 months, to cross-over from control arm ( saline solution ) to the treatment arm (homologous prp). patients will be followed-up with clinical evaluation at 1,3 and 6 months. during the follow-up visits ,will be evaluated the inflammatory status of the knee by thermographic assessment. patients in the treatment arm (homologous prp) will be followed for an additional 6 months (up to 12 months of follow-up). after 6 months, patients in the control arm have the possibility to cross-over into the treatment arm, in which case they will be followed for an additional 12 months.

Eligibility criteria:
inclusion criteria: 1. unilateral involvement; 2. signs and symptoms of degenerative pathology of the knee cartilage; 3. radiographic or mri signs of degenerative pathology of the knee cartilage (kellgren-lawrence 1-4 grades); 4. ability and consent of patients to actively participate in clinical follow-up; 5. signature of informed consent exclusion criteria: 1. patients undergoing knee surgery within the previous 12 months; 2. patients with malignant neoplasms; 3. patients with rheumatic diseases; 4. patients with diabetes; 5. patients with hematologic diseases (coagulopathies); 6. patients with metabolic disorders of the thyroid gland; 7. patients abusing alcoholic beverages, drugs or medications 8. body mass index \> 35

Keywords: knee knee osteoarthritis prp homologous prp prp injections injection treatment randomized controlled trial osteoarthritis
synovitis in patients with osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: to study synovial membrane (sm) inflammation in suprapatellar fossa in advanced knee osteoarthritis (oa), and to correlate the pathological features with clinical findings.


Eligibility criteria:
inclusion criteria: * patients undergoing elective, unilateral, primary tka for advanced osteoarthritis. exclusion criteria: - revisions, bilateral procedures, alcohol or medical abuse, administration of any glucocorticoids during the 3 months prior to surgery, and/or a history of serious cardiac or cerebrovascular problems, severe liver or kidney failure, and/or connective tissue disease including rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus.
quality control of ce-certified phonak hearing aids - 2020_43

Conditions: Hearing Loss

Summary: phonak hearing systems pass through different development and study stages. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. afterwards, and prior to product launch, the phonak hearing systems undergo a final quality control in terms of clinical trials. this is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. this will be a clinical investigation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

the study will compare different features of the phonak behind the ear device activated and deactivated, for example the noise reduction feature. there shall be differences in listening effort, awareness and sound quality shown. the study shall show the advantages especially for people with severe to profound hearing losses. this will be a clinical investigation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

Eligibility criteria:
inclusion criteria: * adult hearing impaired persons (minimum age: 18 years, severe to profound hearing loss) * good written and spoken (swiss) german language skills * healthy outer ear * ability to fill in a questionnaire (p/ecrf) conscientiously * willingness to wear behind-the-ear hearing aids * informed consent as documented by signature exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result * known psychological problems
comparison of emr-p with conventional emr

Conditions: Colonic Polyp

Summary: colorectal cancer is the third most common cancer in men and the second most common cancer in women.there are about 14 million cases of colonoscopy in the united states every year. in recent years, the incidence of colorectal cancer in china has risen sharply, becoming a serious threat to people's health.for small(≤ 9mm) lesions, endoscopic biopsy forceps and cold snare polypectomy can be used to remove.for larger lesions, especially laterally spreading tumor,endoscopic mucosal resection is a classic method of treatment.with the increasing diameter of the lesion size(\> 20mm),we also need to adopt endoscopic piecemeal mucosal resection or endoscopic submucosal dissection. as it, hook knife, bb, and other devices appear constantly, foreign researchers recently adopted a variation of conventional emr（cemr）, namely endoscopic mucosal resection with circumferential precutting(emr - p).the technology is superior to conventional emr for 10 to 20 mm polyps.moreover, preliminary studies suggest that it has good safety and efficacy, and may be a better method for treatment of 10-20mm polyps under colonoscopy. this clinical trial is being conducted to compare the efficacy and safety of two methods of polypectomy, cemr and emr-p, for 10-20mm colorectal polyps.


Eligibility criteria:
inclusion criteria: * one polyp or lesion of 10-20mm at the most proximal of colorectal * adult patients (≥18 years old) * polyps other than pedicled polyps exclusion criteria: * there was submucosal infiltration under endoscope * residual lesions after endoscopic resection * inflammatory bowel disease, familial polyps, electrolyte abnormalities, coagulation disorders, or severe organ failure * pregnant or nursing * no informed consent has been signed * patients taking nsaids or other anticoagulants * sedated colonoscopy
effects of n-3 polyunsaturated fatty acids on chylomicron secretion and expression of genes that regulate intestinal lipid metabolism in men with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the overaccumulation of apob-48-containing lipoproteins of intestinal origin seen in patients with type 2 diabetes are now thought to be attributable to elevated intestinal production and reduced clearance. substantial evidence exists indicating that elevated plasma levels of these lipoproteins are associated with increased cardiovascular disease risk. therefore, reduction of atherogenic plasma triglyceride-rich lipoproteins (trl) levels of intestinal origin appears to be crucial to improve cvd risk associated with type 2 diabetes. in this regard, n-3 pufas have been shown to exert beneficial effects on diabetic dyslipidemia. however, the investigators understanding of the physiological changes that occur with n-3 pufa supplementation is suboptimal, thereby limiting the investigators appreciation of its impact on cvd risk associated with type 2 diabetes. the effects of n-3 pufas on the intestinal production of trls and the expression of genes regulating intestinal lipid absorption and chylomicron synthesis have not yet been examined in humans. the general objective of the proposed research is to investigate the mechanisms by which n-3 pufas beneficially modify intestinal lipoprotein metabolism in patients with type 2 diabetes. the investigators hypothesize that n-3 pufa supplementation in men with type 2 diabetes will: * reduce trl apob-48 production rate and increase fractional catabolic rate of these lipoproteins, * decrease the expression of genes that regulate intestinal lipid absorption and synthesis as well as synthesis of apob-48-containing lipoproteins, * decrease both plasma surrogates of cholesterol absorption and cholesterol synthesis.


Eligibility criteria:
inclusion criteria: * age between 18 and 55 years, * plasma tg levels above the 50th percentile for age, * non-smoker, * bmi between 25.0 and 40.0 kg/m2, * stable body weight for at least 6 months prior to the study baseline, * hba1c between 6.5 and 8.5%, * baseline fasting plasma glucose \< 15.0 mmol/l * patients with de novo type 2 diabetes not taking oral hypoglycemic agents -- - or patients having received stable doses of metformin for at least 3 months before randomization. exclusion criteria: * extreme dyslipidemias such as familial hypercholesterolemia, * patients with secondary form of diabetes or acute metabolic diabetic complications, * patients having received or being treated with insulin or a thiazolidinedione within the past 6 months, * subjects having cvd (chd, cerebrovascular disease or peripheral arterial disease) * subjects taking medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, * significant alcohol intake
the danish childhood obesity biobank

Conditions: Obesity; Metabolic Disease; NAFLD, Non-alcoholic Fatty Liver Disease; Cardiovascular Diseases

Summary: the danish childhood obesity biobank aims to produce a scientific platform for research in obesity: bio-clinical data are collected from two cohorts - an obesity clinic cohort and a population-based cohort. the biobank thus facilitates translation between research and clinical practice of obesity treatment and related complications.

the danish childhood obesity biobank collects data from two cohorts - an obesity clinic cohort and a population-based cohort, of which the latter functions as a reference group. the biobank continuously and longitudinally includes clinical data and biological samples from children and adolescents in obesity treatment. the population-based cohort has been recruited in a cross-sectional manner from danish schools, high schools, and dentistries. data included in the biobank include venous blood samples, stool, urine, saliva, anthropometrics, body composition by dual-energy x-ray absorptiometry, magnetic resonance imaging and spectroscopy, and genetic markers among others. the data are stored in a central secured electronic database and biological materials are stored in -80-degree celsius freezers until analyses. to date, the danish childhood obesity biobank have included data from more than 5250 children, adolescents and adults from the obesity clinic cohort and more than 4200 from the population-based cohort.

Eligibility criteria:
inclusion criteria: * 2- 100 years old * adipose, bmi \> 90 % percentile
carotid intima media thickness (cimt) in epistaxis

Conditions: Epistaxis; Atherosclerosis

Summary: epistaxis is a very frequent emergency among adults and often needs specialised treatment in an ent-department. among others, atherosclerosis is often named as a reason for an increased risk for epistaxis. to evaluate whether or not this is the case, the investigators examined the carotid intima media thickness via ultrasound in patients who were treated in the ent-department of the university hospital of zurich.


Eligibility criteria:
inclusion criteria: * active or very recently active anterior or posterior epistaxis * at least 18 years old exclusion criteria: * posttraumatic or postoperative epistaxis
fostering resilience in physician moms

Conditions: Stress, Psychological

Summary: physicians in general are at risk for burnout, and this risk is heightened among women, particularly mothers. in a randomized design, central hypotheses in this study are that mothers who attend our 12-week relational psychotherapy mothers group (rpmg) intervention will show significantly greater decreases in stress, depression, burnout, and associated risk biomarker indices, as compared to comparison controls (who would meet in unstructured gatherings, for an hour a week for 12 weeks). additionally the investigators hypothesize that the gains would be maintained three months after the intervention is completed.


Eligibility criteria:
inclusion of women and minorities: * this study will be restricted to women physician mothers, who are the target of the manualized rpmg program. * the study will not use race or ethnicity as a basis for selecting subjects. inclusion of children: * this study does not include children. exclusion criteria * participation in this study is open to all mayo physician mothers with a child under the age of 18 years. * as in past rpmg trials, the only exclusion criteria are if mothers were to indicate active suicidality, or meet criteria for psychoses, during initial assessments or during participation in this study.

Keywords: resilience